Oxford Biomedica PLC 2019 AR2
The report highlights Oxford Biomedica's operational and financial performance for the fiscal year 2019, emphasizing its leadership in gene and cell therapy. Key achievements include a five-year extension of its commercial supply agreement with Novartis and a new partnership with Santen Pharmaceutical. The company also made significant progress on its Oxbox bioprocessing facility and established a collaboration with Microsoft Research to apply artificial intelligence to vector development. Environmentally, the company mapped its environmental management system against ISO 14001 and reported its greenhouse gas emissions.
Company: Oxford Biomedica PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2019
Type: AR2
Pages: 158
Back to company
Oxford Biomedica PLC
Annual Report And Accounts
The report highlights Oxford Biomedica's operational and financial performance for the fiscal year 2019, emphasizing its leadership in gene and cell therapy. Key achievements include a five-year extension of its commercial supply agreement with Novartis and a new partnership with Santen Pharmaceutical. The company also made significant progress on its Oxbox bioprocessing facility and established a collaboration with Microsoft Research to apply artificial intelligence to vector development. Environmentally, the company mapped its environmental management system against ISO 14001 and reported its greenhouse gas emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Women in Management
Employees